Wasif M. Saif

Therapeutic human monoclonal antibodies against cancer.

There are over 30 monoclonal antibodies that are FDA approved for a variety of diseases ranging from malignancies to autoimmune diseases to macular degeneration. These antibodies include murine, fully humanized, and chimeric antibodies. There are a number of monoclonal antibodies used in the treatment of malignancies; in fact, three of the top five grossing antibodies (bevacizumab, trastuzumab, and rituximab) are used in oncology Scolnik (mAbs 1:179-184, 2009).

Does OPTINAB strategy ("stop-and-go") work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel (nab) - gemcitabine (gem)?

e15672Background: MPACT study showed survival benefit of nab-gem vs. gem in APC [Von Hoff D, NEJM 2013]. Sensory peripheral neuropathy is a dose-limiting toxicity associated with nab. Neuromodulato...

Adoptive Cell Therapy for Colon Cancer: the Right Choice?

Despite significant advances in the treatment and prognosis of colorectal cancer (CRC), not all tumors respond to current treatment modalities and patients with advanced disease continue to have a poor prognosis. New treatment strategies are needed to improve long-term survival in colorectal cancer patients with metastatic disease. Adoptive cell therapy is a novel approach that uses one’s own immune cells to target tumor cells directly. For the last two decades, a wide variety of methods have been described. T-lymphocyte-based immunotherapy may be a promising alternative treatment capable of mediating durable regressions in patients with advanced colorectal cancer.